MIST Milestone Pharmaceuticals Inc.

BEARISH Impact: 6/10 EFFECT
Horizon weeks Filed May 26, 2026 Processed 20d 1h ago SEC 9999999995-26-001747
IPO/offering going effective
Latest settled — T+5d
MIST ▼ -5.71% at T+5d
SHORT call ✓ call won +5.71% · α vs SPY +6.93% · entry $1.40 → $1.32
Next anchor: T+20d in 9d
Last close $1.27 (close Jun 12) · +9.29% from $1.40 entry (call sign-flipped)
Entry anchored
May 26, 2026
via day open
T+1d
0.00%
call 0.00% · α +0.01%
$1.40
settled 19d ago
T+5d
-5.71%
call +5.71% · α +6.93%
$1.32
settled 13d ago
T+20d
call — · α —
in 9d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Milestone Pharmaceuticals' $300M universal shelf registration (S-3, File No. 333-295860) became effective on May 22, 2026. This allows the company to sell securities, including up to $100M via an ATM facility with Cantor Fitzgerald, creating potential dilution overhang of up to ~44% at current market cap. The shelf is opportunistic to fund commercial launch of CARDAMYST and AFib-RVR development, not distress-driven, given $184.2M cash runway into H2 2027.

Actionable Insight

The effective shelf creates a persistent dilution overhang. Monitor for any takedown announcements or ATM sales, which would accelerate dilution. The cross-filing amplifier (effect-ipo-context + effect-shelf-context) suggests this is a material event; watch for pricing of any offering within 1-2 days.

Key Facts

  • Shelf registration (S-3) declared effective on May 22, 2026
  • Total offering size: $300M universal shelf, including $100M ATM facility
  • Potential dilution of up to ~44% at current $176M market cap
  • Cash runway of $184.2M into H2 2027 per prior Q1 2026 earnings
  • Q1 2026 showed $0.2M CARDAMYST revenue but net loss widened to $26.1M

Financial Impact

Up to $300M in potential securities sales, with $100M ATM facility representing ~57% of current market cap

dilutioncash runwayshare count

Risk Factors

  • Immediate dilution risk if company taps ATM or underwritten offering
  • Stock price pressure from overhang even without actual sales
  • Commercial execution risk for CARDAMYST with limited revenue so far

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (12 analysts)

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-001747
Document: 9999999995-26-001747-index.html9999999995-26-001747
Document: 9999999995-26-001747.txt9999999995-26-001747
6 reports for MIST
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MIST — sortable, filterable
Type Now
May 26, 2026
20d ago
EFFECT
BEARISH ★ 6/10
$1.40 $1.32▲ +5.71%▲ +6.93%$1.27 (+9.29%)
May 13, 2026
4w ago
S-3
BEARISH ★ 6/10
$1.63 $1.52▲ +6.75%▲ +6.03%$1.27 (+22.09%)
May 13, 2026
4w ago
8-K
NEUTRAL ★ 5/10
$1.72 $1.43▼ −16.86%▼ −15.70%$1.27 (−26.16%)
May 13, 2026
4w ago
Press Release
NEUTRAL ★ 5/10
$1.72 $1.43▼ −16.86%▼ −15.70%$1.27 (−26.16%)
Mar 20, 2026
12w ago
Press Release
BULLISH ★ 8/10
$1.36 $1.04▼ −23.53%▼ −21.38%$1.27 (−6.62%)
Mar 16, 2026
12w ago
Press Release
MIXED ★ 5/10
$1.69 $1.26▼ −25.44%▼ −23.40%$1.27 (−24.85%)
Showing 6 of 6

US Market Status

Market Closed — Opens in 1h 41m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access